© 2020 MJH Life Sciences and Medical Economics. All rights reserved.
© 2020 MJH Life Sciences™ and Medical Economics. All rights reserved.
Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.